Notably, the suppression of AGXT and increased hepatic oxalate found in our cohort of liver specimens from patients with end-stage MASH were also independent of potential confounding factors, including race, age or sex. The gene discussed is AGXT; the disease is metabolic dysfunction-associated steatohepatitis.